5.12 0.06 (1.19%) | 03-27 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 8.23 | 1-year : | 9.72 |
Resists | First : | 7.05 | Second : | 8.32 |
Pivot price | 5.69 | |||
Supports | First : | 4.98 | Second : | 4.15 |
MAs | MA(5) : | 5.19 | MA(20) : | 6.16 |
MA(100) : | 5.87 | MA(250) : | 5.44 | |
MACD | MACD : | -0.5 | Signal : | -0.4 |
%K %D | K(14,3) : | 6 | D(3) : | 7.4 |
RSI | RSI(14): 35.2 | |||
52-week | High : | 8.59 | Low : | 3.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CRBU ] has closed above bottom band by 32.9%. Bollinger Bands are 82.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 5.18 - 5.22 | 5.22 - 5.24 |
Low: | 4.98 - 5.02 | 5.02 - 5.05 |
Close: | 5.07 - 5.13 | 5.13 - 5.18 |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Wed, 27 Mar 2024
Investors in Caribou Biosciences (NASDAQ:CRBU) from a year ago are still down 46%, even after 11% gain this past ... - Yahoo Movies UK
Mon, 25 Mar 2024
Caribou Biosciences (NASDAQ:CRBU) Trading 6.5% Higher - MarketBeat
Sat, 23 Mar 2024
Exchange Traded Concepts LLC Buys 6066 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Sat, 23 Mar 2024
Aura Biosciences (NASDAQ:AURA) & Caribou Biosciences (NASDAQ:CRBU) Head-To-Head Survey - Defense World
Thu, 21 Mar 2024
Q1 2024 Earnings Forecast for Caribou Biosciences, Inc. (NASDAQ:CRBU) Issued By HC Wainwright - MarketBeat
Thu, 14 Mar 2024
Caribou Biosciences (NASDAQ:CRBU): Recent Price Volatility May Offer Investors an Entry Point - TipRanks.com - TipRanks
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 90 (M) |
Held by Insiders | 6.848e+007 (%) |
Held by Institutions | 12.4 (%) |
Shares Short | 10,120 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.1253e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | -296.1 % |
Operating Margin | -1 % |
Return on Assets (ttm) | 52.3 % |
Return on Equity (ttm) | -18 % |
Qtrly Rev. Growth | 3.448e+007 % |
Gross Profit (p.s.) | -1.39 |
Sales Per Share | -11.78 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -1.4 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -93 (M) |
PE Ratio | -0.01 |
PEG Ratio | -0.3 |
Price to Book value | 0 |
Price to Sales | -0.44 |
Price to Cash Flow | 3.18 |
Dividend | 0 |
Forward Dividend | 9.39e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |